ExpressionEdits Ltd
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Platform for Therapeutics
ExpressionEdits is a University of Cambridge spin-out advancing biotechnology by enabling it to “speak” nature’s genetic language. Founded by Dr Kärt Tomberg and Professor Allan Bradley, the company has developed the world’s first AI-driven Genetic Syntax Engine, trained on billions of data points from years of proprietary experiments.
Today’s synthetic transgenes lack the intron–exon architecture characteristic of natural genes, a fundamental mismatch that limits RNA processing, export, and stability. ExpressionEdits’ intronized designs recreate this natural structure, yielding superior RNA quality and higher protein expression across biologics and gene therapies.
The company has built the largest and highest-quality dataset in the field, validated its platform through licensing deals, including a multi-asset partnership with Boehringer Ingelheim in gene therapy, and is advancing an internal pipeline of recombinant protein therapeutics, with a lead program in hematology.
Company HQ City:
Cambridge
Company HQ State:
Cambridgeshire
Company HQ Country:
United Kingdom
Year Founded:
2021
Lead Product in Development:
Undisclosed haematology asset
CEO
Dr Kärt Tomberg
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
June 2026
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}